Genetic & Epigenetic Events in Papillary Thyroid Cancer
遗传
基本信息
- 批准号:7840386
- 负责人:
- 金额:$ 28.27万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-07-01 至 2013-05-31
- 项目状态:已结题
- 来源:
- 关键词:AcetylationBRAF geneCancer PatientCell LineCellsDNADNA MethylationDNA MethyltransferaseDNA Modification MethylasesDNA SequenceDNA Sequence RearrangementDeacetylationDevelopmentDominant-Negative MutationEndocrineEpigenetic ProcessEventFailureFrequenciesGene ExpressionGene SilencingGenesGeneticGenomicsGoalsHistone DeacetylationHistonesHumanIodidesMAP Kinase Activation PathwayMAP Kinase Signaling PathwaysMEKsMalignant NeoplasmsMalignant neoplasm of thyroidMessenger RNAMetabolismMethodsMethylationMitogen-Activated Protein KinasesModelingModificationMolecularMorbidity - disease rateMutationOncogene ProteinsOncogenicPapillary thyroid carcinomaPathogenesisPathway interactionsPatternPhosphotransferasesPlayPrincipal InvestigatorProcessProteinsRNARNA InterferenceRas/RafRelative (related person)Reverse Transcriptase Polymerase Chain ReactionRoleSLC5A5 geneSmall Interfering RNATechniquesTestingThyroid GlandThyrotropin ReceptorTimeTransfectionTumor Cell LineTumor Suppressor GenesVariantWestern Blottingbasebisulfitechromatin immunoprecipitationexpression vectorhistone modificationinhibitor/antagonistkinase inhibitormalignant endocrine gland neoplasmmortalitymutantneoplastic cellnew therapeutic targetprogramspromoterreceptorsodium-iodide symporterthyroid neoplasmtumortumorigenesis
项目摘要
DESCRIPTION (provided by applicant): Papillary thyroid cancer (PTC), the most common endocrine malignancy, harbors several important oncogenic events, including BRAF mutation, Ras mutation, RET/PTC rearrangements, and methylation- induced silencing of the tumor suppressor gene RASSF1 A. Silencing of the thyroid-specific genes that are involved in iodide metabolism, such as the genes for thyroid-stimulating hormone receptor (TSHR) and sodium/iodide symporter (NIS), is responsible for the failure of some PTC patients to respond to radioiodine treatment. It is hypothesized that the oncogenic events, by activating the MAP kinase pathway, result in epigenetic alterations that are responsible for thyroid-specific gene silencing. To test this hypothesis, mutual exclusivity of the oncogenic events will first be tested in specific subtypes of PTC to support the concept that each oncogenic event is able to cause PTC through activating their shared MAP kinase pathway. Methylation status of thyroid-specific genes will be subsequently examined in the same tumors, with a focus on the TSHR and NIS genes, to define the relationship of oncogenic events with thyroid gene methylation. Human thyroid tumor cell lines with various oncogenic alterations, either naturally existing or experimentally created, will be used to study the functional relationship between the oncogenic events and thyroid gene methylation. Epigenetic histone modification and its relationship to DNA methylation in silencing thyroid genes and to oncogenic alterations will also be studied in cell lines. Specific kinase inhibitors and cell transfection with oncoproteins and siRNAs will be used to alter MAP kinase pathway activities in these studies. The role of BRAF mutation, the most common oncogenic event in PTC, and related MAP kinase pathway aberration in the epigenetic alteration and silencing of thyroid-specific genes will be the primary focus of these studies. We expect to discover important molecular information on the mechanisms of PTC pathogenesis and novel therapeutic targets for this most common endocrine cancer.
描述(由申请人提供):甲状腺乳头状癌(PTC)是最常见的内分泌恶性肿瘤,具有几种重要的致癌事件,包括BRAF突变、Ras突变、RET/PTC重排和甲基化诱导的肿瘤抑制基因RASSF 1A沉默。参与碘代谢的甲状腺特异性基因的沉默,例如促甲状腺激素受体(TSHR)和钠/碘同向转运体(NIS)的基因,是一些PTC患者对放射性碘治疗反应失败的原因。据推测,致癌事件,通过激活MAP激酶途径,导致表观遗传改变,负责甲状腺特异性基因沉默。为了检验这一假设,将首先在PTC的特定亚型中检验致癌事件的互斥性,以支持每个致癌事件能够通过激活其共享的MAP激酶途径引起PTC的概念。随后将在相同的肿瘤中检查甲状腺特异性基因的甲基化状态,重点是TSHR和NIS基因,以确定致癌事件与甲状腺基因甲基化的关系。具有各种致癌改变的人甲状腺肿瘤细胞系,无论是天然存在的还是实验创建的,将用于研究致癌事件和甲状腺基因甲基化之间的功能关系。还将在细胞系中研究表观遗传组蛋白修饰及其与沉默甲状腺基因的DNA甲基化和致癌改变的关系。在这些研究中,特异性激酶抑制剂和癌蛋白和siRNA的细胞转染将用于改变MAP激酶途径活性。BRAF突变,PTC中最常见的致癌事件,以及相关的MAP激酶通路畸变在甲状腺特异性基因的表观遗传改变和沉默中的作用将是这些研究的主要焦点。我们期望发现PTC发病机制的重要分子信息和这种最常见的内分泌癌的新治疗靶点。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MICHAEL Mingzhao XING其他文献
MICHAEL Mingzhao XING的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MICHAEL Mingzhao XING', 18)}}的其他基金
Genome-wide Exploration of DNA Methylation Markers for Thyroid Cancer
甲状腺癌 DNA 甲基化标记的全基因组探索
- 批准号:
8634084 - 财政年份:2013
- 资助金额:
$ 28.27万 - 项目类别:
Genome-wide Exploration of DNA Methylation Markers for Thyroid Cancer
甲状腺癌 DNA 甲基化标记的全基因组探索
- 批准号:
8492305 - 财政年份:2013
- 资助金额:
$ 28.27万 - 项目类别:
Molecular Events in the PI3K/Akt Pathway in Thyroid Cancer
甲状腺癌 PI3K/Akt 通路中的分子事件
- 批准号:
8074952 - 财政年份:2009
- 资助金额:
$ 28.27万 - 项目类别:
Molecular Events in the PI3K/Akt Pathway in Thyroid Cancer
甲状腺癌 PI3K/Akt 通路中的分子事件
- 批准号:
8474705 - 财政年份:2009
- 资助金额:
$ 28.27万 - 项目类别:
Molecular Events in the PI3K/Akt Pathway in Thyroid Cancer
甲状腺癌 PI3K/Akt 通路中的分子事件
- 批准号:
8264949 - 财政年份:2009
- 资助金额:
$ 28.27万 - 项目类别:
Molecular Events in the PI3K/Akt Pathway in Thyroid Cancer
甲状腺癌 PI3K/Akt 通路中的分子事件
- 批准号:
7728577 - 财政年份:2009
- 资助金额:
$ 28.27万 - 项目类别:
Genetic and Epigenetic Alterations in Thyroid Tumors
甲状腺肿瘤的遗传和表观遗传改变
- 批准号:
7432579 - 财政年份:2006
- 资助金额:
$ 28.27万 - 项目类别:
Genetic and Epigenetic Alterations in Thyroid Tumors
甲状腺肿瘤的遗传和表观遗传改变
- 批准号:
7244434 - 财政年份:2006
- 资助金额:
$ 28.27万 - 项目类别:
相似海外基金
BRAF gene mutation causes hallmarks of cancer associated with tumor microenvironment
BRAF基因突变导致与肿瘤微环境相关的癌症特征
- 批准号:
18K14582 - 财政年份:2018
- 资助金额:
$ 28.27万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Significance of BRAF gene mutation on tumor microenvironment
BRAF基因突变对肿瘤微环境的意义
- 批准号:
16K20968 - 财政年份:2016
- 资助金额:
$ 28.27万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Evaluation of radiation effect based on point mutation of BRAF gene
基于BRAF基因点突变的放射效果评价
- 批准号:
15K12202 - 财政年份:2015
- 资助金额:
$ 28.27万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
Analysis of tumor clonality using SNPs surrounding BRAF gene and its association with clinicopathological features
BRAF基因周围SNP分析肿瘤克隆性及其与临床病理特征的关系
- 批准号:
19790651 - 财政年份:2007
- 资助金额:
$ 28.27万 - 项目类别:
Grant-in-Aid for Young Scientists (B)